Driven by several blockbuster products, the biopharmaceutical contract manufacturing market has evolved considerably

Biologics represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized pharmacological interventions.

Although biopharmaceuticals offer significant profit margins and have demonstrated the potential to treat a myriad of disease indications, they are generally associated with high costs of development and complex manufacturing protocols. This has compelled many biopharmaceutical developers to outsource various aspect of their operations to contract service providers. The biopharmaceutical contract manufacturing market is presently characterized by the presence of both niche, specialty companies, focused on early-stage development and production (preclinical and / or clinical scales), and one-stop-shops, which have, over time, acquired an extensive range of capabilities to cater to essentially all the product development and commercialization requirements of sponsors. Detailed services that are commonly offered by biopharmaceutical contract manufacturers.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/250/request-

It is worth highlighting that there is a significant rise in the interest of stakeholders in biopharmaceutical contract manufacturing segment; this can be validated by the increase in partnership and funding activity within this domain. It is evident that most of the biopharmaceutical CMOs have the required capabilities to operate at all scales of operation, followed by those capable of operating at both clinical and commercial scales. Further, the growing demand for biologics has compelled the players engaged in this domain to expand their existing capabilities / capacities in order to accommodate the future needs of their clients. it is worth noting that majority of the CMOs are currently using mammalian expression systems (29%), for manufacturing of biologics, followed by those using both mammalian and microbial expression systems (26%). In addition, as mentioned earlier, innovation in this field, coupled to the development of novel fermentation technologies, has further expediated the growth of biopharmaceutical contract manufacturing segment.

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

 

www.rootsanalysis.com

Request Sample - Biopharmaceutical Contract Manufacturing Market (Biopharma CDMO) | Industry Analysis | 2035

With over 450 manufacturing facilities and rising biologics demand, biopharmaceutical contract manufacturing market (biopharma CDMO) is expected to grow at nearly 10% CAGR

https://docplusindia.com/hymen....oplasty-surgery-in-b

 

docplusindia.com

Hymenoplasty Surgery in India | Vaginoplasty Surgery in Bangalore - Doc+India

Get Hymenoplasty Surgery in India, Bangalore. Doc+India provides affordable Vaginoplasty Surgery in Bangalore by the Best Cosmetic/plastic surgeons in India.

The AI-based digital pathology market is projected to grow at an annualized rate of 8.3%, claims Roots Analysis

Driven by continuous innovation within pathology subdomains to improve care delivery paradigms across clinical practices, and active R&D efforts undertaken by industry stakeholders, the AI based digital pathology market is likely to witness significant growth in the coming years

Roots Analysis has announced the addition of “AI-based Digital Pathology Market, 2022-2035” report to its list of offerings.

The use of technical advancements to automate and digitize medical operations is expanding, in conjugation with the continuously growing need for pathology services. These innovations have recently expedited clinical diagnosis and research, as well as improved patient outcomes. Given the rise in popularity and demand for such services in the healthcare and research sectors, as well as the ongoing efforts of AI in pathology providers to enhance their respective portfolios, this market is expected to grow at a steady pace, till 2035.


Key Market Insights

Presently, close to 80 players are actively providing AI-based digital pathology services
More than 45% of the players are located in North America. Within North America, 85% of the AI-based digital pathology providers are based in the US. Further, the domain primarily features the presence of small companies (less than 50 employees), which constitute over 45% of the overall share.

More than 60% of companies provide whole slide imaging and laboratory information systems
Majority (70%) of the players are providing whole slide imaging for research applications. Additionally, over 20% of such players are offering the aforementioned service for diagnostic applications. Further, 72% of the players are providing laboratory information systems for research purposes.

~75% AI-based digital pathology providers are offering their services to research institutes
Close to 60 companies are offering services to research institutes. Further, 48 companies are providing its services to laboratories / diagnostic institutions. It is worth highlighting that close to 30 AI-based digital pathology providers are offering their services to hospitals / healthcare institutions.

Over 35% players are offering AI-based digital pathology services for detection of breast cancer
More than 50% of players are offering Ki67 assay. Among other target disease indications, Ki67 is primarily used to detect breast cancer. Further, close to 25% of players are offering AI-based digital pathology services to detect prostate cancer.

USD 1.7+ billion has been invested across different funding rounds, between 2016 and 2022
Companies involved in offering AI-based digital pathology services have raised more than USD 900 million through venture capital rounds, which represents 55% of the total capital raised in this market between 2016 to 2022. Further, close to 15% of investments have been raised via seed rounds.

Global demand for AI-based digital pathology is expected to grow at a CAGR of 9.4%, during 2022-2035
In 2035, more than 45% of the overall demand for AI-based digital pathology services is anticipated to be driven by research institutes. Furthermore, it is projected that North America (43%) will drive a majority share of the global demand for AI-based digital pathology services.

The market in Middle East and North Africa is anticipated to grow at a faster pace (14.1%), till 2035
Considering the anticipated notable increase in demand for AI-based digital pathology services, over the coming years, this billion-dollar market is expected to be well distributed across key segments. Services focused on research applications are expected to capture close to 50% of the market share by 2035.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/....reports/ai-based-dig

Key Questions Answered
 Who are the leading players engaged in offering AI-based digital pathology in the healthcare domain?
 Which geographies emerged as key hubs for AI-based digital pathology providers?
 Which types of end-users are primarily employing AI in digital pathology in their regular workflow?
 What type of funding initiatives are most commonly being reported by stakeholders in this domain?
 What are the key strategies that can be implemented by emerging players to enter the AI-based digital pathology market?
 What are the key market trends and driving factors that are likely to impact the growth of the AI-based digital pathology market?
 How is the current and future opportunity likely to be distributed across key market segment?

The financial opportunity within the AI-based digital pathology market has been analyzed across the following segments:

 Type of Neural Network
 Artificial Neural Network
 Convolutional Neural Network
 Fully Convolutional Network
 Recurrent Neural Network
 Other Neural Networks

 Type of Assay
 ER Assay
 HER2 Assay
 Ki67 Assay
 PD-L1 Assay
 PR Assay
 Other Assays

 End-user
 Academic Institutions
 Hospitals / Healthcare Institutions
 Laboratories / Diagnostic Institutions
 Research Institutes
 Other End-users

 Area of Application
 Diagnostics
 Research
 Other Areas of Application

 Target Disease Indication
 Breast Cancer
 Colorectal Cancer
 Cervical Cancer
 Gastrointestinal Cancer
 Lung Cancer
 Prostate Cancer
 Other Indications

 Key Geographies
 North America
 Europe
 Asia
 Latin America
 Middle East and North Africa
 Rest of the World

 Key Countries
 US
 Canada
 UK
 Germany
 Spain
 Italy
 France
 China
 Japan
 South Korea
 Brazil
 Saudi Arabia
 Australia

The report features inputs from eminent industry stakeholders, according to whom, AI-based digital pathology is increasingly being recognized in the healthcare industry. The report includes detailed transcripts of discussions held with the following experts:
 Joe Yeh (Chief Executive Officer and Chairman, aetherAI)
 Suraj Bramhane (Laboratory Director and Chief Pathologist, Clinitech Laboratory)
 Savvas Damaskinos (Vice President, Research and Technology, Huron Digital Pathology)
 Anil Berger (Vice President, Sales and Marketing, Mindpeak)
 Scott Wallace (Vice President, Business Development and Strategic Partnerships, Pramana)

The report includes brief profiles of key players (listed below); each profile features an overview of the company and recent developments related to its AI-based digital pathology offerings:
 PathAI
 Paige
 Akoya Biosciences
 PROSCIA
 Visiopharm
 Roche Tissue Diagnostics
 Aiforia Technologies
 Indica Labs
 Ibex Medical Analytics

For additional details, please visit https://www.rootsanalysis.com/....reports/ai-based-dig or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. 4D Bioprinting Market : Industry Trends and Global Forecasts, 2022-2035


About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

The TIL-based therapy market is projected to grow at an annualized rate of 40%, claims Roots Analysis

Owing to their tumor-killing capability and therapeutic superiority to conventional therapies, TIL-based therapies are being actively evaluated to treat advance, incurable oncological disorders by various researchers and industry stakeholders.

Owing to their tumor-killing capability and therapeutic superiority to conventional therapies, TIL-based therapies are being actively evaluated to treat advance, incurable oncological disorders by various researchers and industry stakeholders.

Roots Analysis has announced the addition of “Global TIL-based Therapy Market (2nd Edition), 2023-2035” report to its list of offerings.
Given the limitations associated with conventional cancer treatment options, there has been a surge in the need for more effective, safe and versatile alternatives, such as TIL-based therapies. Driven by a promising development pipeline and encouraging clinical trial results, the tumor infiltrating lymphocytes therapies market is likely to carve out a significant share of the cancer immunotherapy market.

Key Market Insights
Over 75 TIL-based therapies are currently approved / under development
Close to 83% of the TIL-based therapies are being evaluated in clinical trials (phase I and above), while 17% of them are in preclinical stage of development. More than 95% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, more than 75% of these are combination therapies.

More than 3,800 patients have been enrolled in nearly 95 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, over 65% are active and still recruiting patients, while more than 25% have already been completed.

Partnership activity within this domain has grown at a CAGR of 29%, between 2015 and 2021
Majority of the agreements related to TIL-based therapies were observed to be R&D agreements, representing close to 40% of the total partnerships. Further, most of the intercontinental, as well as intracontinental, deals have been inked by players based in North America.

Over 2.7 USD billion has been invested by both private and public investors in this domain, since 2013
Industry players raised over USD 1.4 billion in the past 3 years. In addition, majority (37%) of the companies received funding through secondary offering rounds. Further, close to USD 540 million were invested by private firms.

More than 160 patents have been filed / published related to the TCR-based therapies
Close to 75% of the filed / published patents were patent applications, followed by granted patents (25%). Of the total granted applications, more than 95% were filed in North America.

The TIL market is anticipated to grow at a CAGR of 40%, during the period 2022-2035
In 2035, more than 50% of the market revenues are expected to be generated from sales of therapeutics intended for Melanoma. Further, North America and Europe is anticipated to capture close to 90% of the market share, by 2035.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/til-therapie

Key Questions Answered
 What is the growth rate of TIL-based therapy market?
 Which region has the highest growth rate in the TIL Therapies market?
 How many players are developing TIL-based Therapies?
 Which target indication covers the largest TIL-based therapy market share?
 What is the partnership and collaboration trend in the TIL-based therapy domain?
 What is the current IP landscape of TIL-based therapies market?

The financial opportunity within the TIL-based therapies market has been analyzed across the following segments:
 Target Indication(s)
 Melanoma
 Head and Neck Carcinoma
 Chronic Lymphocytic Leukemia
 Sarcoma
 Hepatocellular Carcinoma
 Breast Cancer
 Acute Myeloid Leukemia
 Cervical Carcinoma

 Key Geographical Regions
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

The report includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), details about TIL-based product(s), such as information on status of development, technology portfolio (if available), recent developments related to TIL-based therapies and manufacturing capabilities of the players.
 Cellectis
 Cellular Biomedicine Group
 Iovance Biotherapeutics
 Lytix Biopharma
 Phio Pharmaceuticals

For additional details, please visit https://www.rootsanalysis.com/....reports/til-therapie or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

 

www.rootsanalysis.com

Request Sample - TIL Therapies Market | Industry Analysis | Market Size | 2035

TIL therapies market, driven by over 75 therapies under development and fueled by over $2.7 billion funding, is likely to grow at over 40% CAGR

Satta King Fast Results 2023 | from 0 to 99
https://sattakingm.in/
https://sattakingg.in/

If you want to play Satta King, you need to know the rules. The game is a lottery that involves picking a number from a Satta Matka. It is a popular gambling game that is played all over the world. You can win up to eighty or ninety times your initial bet.

 

sattakingm.in

Satta king 2023 | Sattaking | Satta result | Satta king online | Satta king live | Satta king result

Get 2023 - Satta King, satta result, satta king up, sattaking, gali result, satta result up, black satta, satta king 786, satta gali, satta king gali, desawar result, faridabaad result, gaziabaad result king

The opportunity within the HPAPI and cytotoxic drug manufacturing market is projected to grow at an annualized rate of ~12%, till 2035, claims Roots Analysis

Highly potent compounds have emerged as one of the key modalities in the healthcare community owing to their numerous advantages, including stable nature, enhanced efficacy at lower doses, selective mechanism of action and significantly lower side effects

Roots Analysis has announced the addition of “HPAPI and Cytotoxic Drug Manufacturing Market (4th Edition), 2022 – 2035” report to its list of offerings.

Manufacturing of highly potent compounds is a laborious procedure, plagued with various difficulties, including high capital investment, extensive operational expertise, as well as access to advanced infrastructure and technologies. As a result, outsourcing has become a preferred business model in this domain, providing increased flexibility, reduced costs and timely launch of drugs. Further, to keep up with the evolving client requirements, several contract manufacturing organizations have upgraded their existing capabilities / facilities.


Key Market Insights

More than 140 companies claim to offer highly potent active pharmaceutical ingredients (HPAPI) and cytotoxic drug contract manufacturing services, globally
Majority (44%) of the industry stakeholders are based in Europe, followed by those having headquarters in North America (35%). Further, more than 30% of the service providers claim to have the required capabilities to manufacture both HPAPIs and highly potent finished dosage forms. It is also worth mentioning that over 50% of the players offer contract manufacturing services for HPAPI and cytotoxic drugs across all the three scales of operation.

Around 35% of partnership agreements were inked post 2020
Majority of the agreements related to HPAPI manufacturing were observed to be instances of acquisitions, representing 21% of the total partnerships. Further, most of the intercontinental, as well as intracontinental, deals have been inked by players based in Europe.

Over 95 expansion initiatives have been observed since 2018
Around 50% of the initiatives were focused on expanding the existing highly potent compound manufacturing facilities, followed by instances of capacity expansions (27%) and new facility additions (24%). More than 65% of the expansions reported in this domain were local initiatives, followed by international initiatives (33%).

Global installed HPAPI contract manufacturing capacity is currently estimated to be more than 2.5 million liters
The maximum share (83%) of the current installed capacity is expected to be captured by very large players. Moreover, close to 40% of the global, installed manufacturing capacity is available with facilities located in the Europe region.

North America and Europe are anticipated to capture more than 70% of the market share, by 2035
The market in Asia Pacific is likely to grow at a relatively faster pace (12.8%), in the long term. Currently, majority share (62%) of the overall HPAPI and cytotoxic drug contract manufacturing market is captured by HPAPIs; this trend is unlikely to change in the foreseen future as well. Further, in 2035, over 80% of the market share is likely to be captured by highly potent small molecules.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/299/request-

Key Questions Answered
 Who are the key players engaged in offering contract manufacturing services for HPAPIs and cytotoxic drugs?
 What are the current opportunities within the HPAPI and cytotoxic drug market?
 What is the relative competitiveness of HPAPI and cytotoxic drug contract manufacturers?
 What types of partnership models are commonly adopted by stakeholders in this industry?
 What are the different types of expansion initiatives being undertaken by HPAPI and cytotoxic drug contract manufacturers?
 What are the key challenges faced by HPAPI and cytotoxic drug contract manufacturers?
 What are the key market trends and driving factors that are likely to impact this market?
 How is the revenue generation potential associated with HPAPI and cytotoxic drug manufacturing market likely to evolve in the coming years?

The financial opportunity within the HPAPI and cytotoxic drug manufacturing market has been analyzed across the following segments:
 Type of Product
 Highly Potent Active Pharmaceutical Ingredient
 Highly Potent Finished Dosage Form

 Company Size
 Small
 Mid-sized
 Large
 Very Large

 Scale of Operation
 Preclinical
 Clinical
 Commercial

 Type of Molecule
 Small Molecules
 Biologics

 Type of Highly Potent Finished Dosage Form
 Injectables
 Oral Solids
 Creams
 Others

 Key Geographical Regions
 North America (US, Canada and Mexico)
 Europe (UK, Italy, Germany, France, Spain and Rest of Europe)
 Asia-Pacific (China, India and Rest of Asia-Pacific)
 Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, continuous growth of the oncological therapeutics pipeline and the increasing preference for outsourcing is likely to drive the growth of the overall HPAPI and cytotoxic drug manufacturing market, in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:
 Justin Mason-Home (Owner and Director, HPAPI Project Service)
 Antonella Mancuso and Maria Elena Guadagno (Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals)
 Scott Patterson (Vice President Pharma/Bio Technical Support, ILC Dover)
 Stacy McDonald and Jennifer L. Mitcham (Ex-Group Product Manager and Ex-Director-Business Development); Abul Khair (Business Development Associate, Catalent)
 Roberto Margarita (Business Development Director, CordenPharma)
 Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)
 Kevin Rosenthal (Ex-Business Head, Formulations and Finished Products, Alphora Research (Acquired by Eurofins))
 Mark Wright (Ex-Site Head, Grangemouth, Piramal)
 Allison Vavala (Ex-Senior Manager, Business Development, Helsinn)
 Valentino Mandelli (Marketing and Sales Manager, Pharma, Cerbios-Pharma)
 Javier E. Aznarez Araiz (Ex-Business Development, Idifarma)

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its financial performance (if available), recent developments and an informed future outlook.
 AbbVie
 Abzena
 Aenova
 Cambrex
 CARBOGEN AMCIS
 Catalent
 Hovione
 Intas Pharmaceuticals
 Lonza
 Pfizer CentreOne
 Piramal Pharma Solutions
 Scinopharm
 STA Pharmaceutical (a WuXi AppTec company)
 Syngene
 Teva API

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Biopharmaceutical Contract Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035
2. ADC Contract Manufacturing Market (5th Edition): Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

Delta Flights to Jamaica | Montego Bay | Skymilesdelta
Experience the beautiful Caribbean island with Delta flights to Jamaica. Book your trip today & enjoy amazing prices.
See more: https://www.skymilesdelta.com/....delta-flights-to-jam

 

www.skymilesdelta.com

Delta Flights to Jamaica | Montego Bay | Skymilesdelta

Experience the beautiful Caribbean island with Delta flights to Jamaica. Book your trip today & enjoy amazing prices.